• M Cattaneo.
• Unità di Ematologia e Trombosi, Ospedale San Paolo, University of Milano, Milano, Italy. marco.cattaneo@unimi.it
• Haemophilia. 2008 Jan 1; 14 Suppl 1: 40-7.

AbstractDesmopressin (l-deamino-8-D-arginine vasopressin, DDAVP) is a synthetic analogue of the antidiuretic hormone vasopressin. Like the natural antidiuretic hormone, desmopressin increases the plasma levels of factor VIII and von Willebrand factor (vWF), with the advantage, compared to vasopressin, that it produces little or no vasoconstriction, no increase in blood pressure, and no contraction of the uterus or gastrointestinal tract, so that it is well tolerated when administered to humans. In 1977, desmopressin was used for the first time in patients with mild hemophilia A and von Willebrand disease (vWD) for the prevention and treatment of bleeding, first during dental extractions and then during major surgical procedures. The clinical indications for desmopressin rapidly expanded beyond hemophilia and vWD. The compound was shown to be efficacious even in bleeding disorders not involving a deficiency or dysfunction of factor VIII or vWF, including congenital and acquired defects of platelet function and such frequent abnormalities of hemostasis as those associated with chronic kidney and liver diseases. Desmopressin has also been used prophylactically in patients undergoing surgical operations characterized by large blood loss and transfusion requirements.

13 keywords...

hide…